Marion De Jong
Department of Nuclear Medicine
L2, Erasmus MC
3015 GD
Netherlands
Name/email consistency: high
- Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. de Jong, M., Kwekkeboom, D., Valkema, R., Krenning, E.P. Eur. J. Nucl. Med. Mol. Imaging (2003)
- New advances in peptide receptor radionuclide therapy. de Jong, M., Krenning, E. J. Nucl. Med. (2002)
- [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. de Jong, M., Breeman, W.A., Bernard, B.F., Bakker, W.H., Schaar, M., van Gameren, A., Bugaj, J.E., Erion, J., Schmidt, M., Srinivasan, A., Krenning, E.P. Int. J. Cancer (2001)
- Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. De Jong, M., Bakker, W.H., Breeman, W.A., Bernard, B.F., Hofland, L.J., Visser, T.J., Srinivasan, A., Schmidt, M., Béhé, M., Mäcke, H.R., Krenning, E.P. Int. J. Cancer (1998)
- Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. de Jong, M., Breeman, W.A., Bakker, W.H., Kooij, P.P., Bernard, B.F., Hofland, L.J., Visser, T.J., Srinivasan, A., Schmidt, M.A., Erion, J.L., Bugaj, J.E., Mäcke, H.R., Krenning, E.P. Cancer Res. (1998)